Nebenwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 14
HOS-113521 · Präparat HOS-093937
Paediatric population The safety database to support once daily dosing in paediatric patients comes from the ARROW Trial (COL105677) in which 669 HIV-1 infected paediatric subjects (from 12 months to ≤17 years old). received abacavir and lamivudine either once or twice daily (see section 5.1). Within this population, 104 HIV-1 infected paediatric subjects weighing at least 25 kg received abacavir and lamivudine as Kivexa once daily. No additional safety issues have been identified in paediatric subjects receiving either once or twice daily dosing compared to adults.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 2e5b8f0f2d0e4cc8ee235406afd814d1667bfc76d2be0acabf153301a1060aae · Zeichen 7581–8153 im Abschnitt